2. Search Result
Search Result
Results for "

endocannabinoids

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-162298
    γ-Linolenoyl monoethanolamide

    		Cannabinoid Receptor Metabolic Disease
    γ-Linolenoyl monoethanolamide, a kind of fatty N-acyl ethanolamine, is an endocannabinoid .
    γ-Linolenoyl monoethanolamide
  • HY-103341
    UCM707

    		Cannabinoid Receptor Neurological Disease
    UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide .
    UCM707
  • HY-114826
    Prostaglandin E2-1-glyceryl ester

    		Cannabinoid Receptor Metabolic Disease Cancer
    Prostaglandin E2-1-glyceryl ester, a Prostaglandin Glycerol Ester, is an endocannabinoid ligand for the CB1 receptor. Prostaglandin E2-1-glyceryl ester induces rapid, transient elevation of intracellular free Ca 2+ .
    Prostaglandin E2-1-glyceryl ester
  • HY-162305
    MAGL-IN-15

    		MAGL Neurological Disease
    MAGL-IN-15 (Compound 6) is a MAGL inhibitor that can be used in the research of diseases and disorders related to the regulation of endocannabinoid system signaling activities .
    MAGL-IN-15
  • HY-125407
    Palmitoyl serinol

    N-Palmitoyl serinol

    		 Cannabinoid Receptor Inflammation/Immunology
    Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin .
    Palmitoyl serinol
  • HY-103332
    N-Arachidonylglycine

    NA-Gly

    		 GlyT Endogenous Metabolite Inflammation/Immunology
    N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration .
    N-Arachidonylglycine
  • HY-152148
    JZP-MA-11

    		MAGL Neurological Disease
    JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) .
    JZP-MA-11
  • HY-132310
    MAGL-IN-4

    		MAGL Neurological Disease
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .
    MAGL-IN-4
  • HY-113015
    Stearoylethanolamide

    		Endogenous Metabolite Neurological Disease
    Stearoylethanolamide is an endocannabinoid-like compound with pro-apoptotic activity.
    Stearoylethanolamide
  • HY-121517
    URB754

    		Others Neurological Disease
    URB754 is a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase (MGL) with an IC50 of 200 nM .
    URB754
  • HY-103340
    O-2093

    		Cannabinoid Receptor Neurological Disease
    O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC50 of 17.3 μM .
    O-2093
  • HY-W747573
    N-Linolenoylethanolamine

    18:3 NAE; α-Linolenoyl ethanolamide

    		 TRP Channel Neurological Disease
    N-Linolenoylethanolamine (18:3 NAE) is an endocannabinoid. N-Linolenoylethanolamine is a vanillin receptor (TRPV1) agonist .
    N-Linolenoylethanolamine
  • HY-W020035
    L-α-lysophosphatidylinositol (Soy) (sodium)

    		GPR55 Neurological Disease
    L-α-lysophosphatidylinositol Soy sodium is an endogenous ligand of GPR55. L-α-lysophosphatidylinositol Soy sodium is an endogenous lysophospholipid and endocannabinoid neurotransmitter that belongs to the class of lysophospholipids .
    L-α-lysophosphatidylinositol (Soy) (sodium)
  • HY-120300
    UCM710

    		Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
    UCM710
  • HY-110004
    ACEA

    Arachidonyl-2-chloroethylamide

    		 Biochemical Assay Reagents Others
    ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory .
    ACEA
  • HY-151107
    CBR Agonist-2

    		Cannabinoid Receptor Neurological Disease
    CBR Agonist-2 is a CB1 agonist (CB1R; CB1 ligand) with an EC50 and a Ki of 960 nM and 970 nM, respectively. CBR Agonist-2 is a promising tool for investigating the involvement of hCB1R in disorders associated with the endocannabinoid system .
    CBR Agonist-2
  • HY-112528
    Glycerophospho-N-palmitoyl ethanolamine

    GP-NPEA

    		 Others Metabolic Disease
    Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .
    Glycerophospho-N-palmitoyl ethanolamine
  • HY-133130
    JNJ-42226314

    		MAGL Neurological Disease
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-125407S
    Palmitoyl serinol-d5

    N-Palmitoyl serinol-d5

    		 Cannabinoid Receptor Inflammation/Immunology
    Palmitoyl serinol-d5 is the deuterium labeled Palmitoyl serinol[1]. Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin[2][3].
    Palmitoyl serinol-d5
  • HY-101388
    AM404

    AM404, an inhibitor of endocannabinoid reuptake, blocks anandamide transport with IC50 values in the low micromolar range . AM404 is able to relax rat isolated hepatic arteries contracted with Phenylephrine, with a pEC50 value of 7.4 (corresponding to an EC50 of 0.04 µM). Neuroprotective Effect .
    AM404
  • HY-146342
    FAAH/MAGL-IN-3

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-146341
    FAAH-IN-5

    		FAAH MAGL Neurological Disease
    FAAH-IN-5 (Compound 7) is a relative selective, irreversible fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH-IN-5
  • HY-116418
    Virodhamine

    		Endogenous Metabolite Cannabinoid Receptor Neurological Disease
    Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases .
    Virodhamine
  • HY-N0313
    Euphol

    		MAGL Endogenous Metabolite Inflammation/Immunology
    Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC50=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain .
    Euphol
  • HY-103463
    SA57

    		FAAH MAGL Neurological Disease
    SA57 is a potent, selective FAAH inhibitor with IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH. SA57 also inhibits the 2-arachidonoylglycerol hydrolases MAGL (IC50s of 410 nM and 1.4 μM for mouse and human MAGL) and mouse α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 of 850 nM), but not other brain serine hydrolases .
    SA57
  • HY-150029
    CB1/2 agonist 3

    		Cannabinoid Receptor Neurological Disease
    CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with Ki values of 5.9 nM and 3.5 nM, respectively .
    CB1/2 agonist 3
  • HY-121996
    Prostaglandin E2 Ethanolamide

    PGE2 ethanolamide

    		 Prostaglandin Receptor COX Inflammation/Immunology
    Prostaglandin E2 Ethanolamide (PGE2-EA), an analog of PGE2, can be formed enzymatically following COX-2 oxygenation of endocannabinoids. Prostaglandin E2 Ethanolamide (PGE2-EA) could modulate the production of the proinflammatory cytokine TNF-α in human blood and human monocytic cells .
    Prostaglandin E2 Ethanolamide
  • HY-77491
    FAAH/MAGL-IN-5

    		FAAH MAGL Neurological Disease
    AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects .
    FAAH/MAGL-IN-5
  • HY-120961
    Oleoyl ethyl amide

    N-Ethyloleamide

    		 FAAH Metabolic Disease
    Oleoyl ethyl amide (N-Ethyloleamide) is a fatty acid amide hydrolase (FAAH) inhibitor. Oleoyl ethyl amide can counteract bladder overactivity .
    Oleoyl ethyl amide
  • HY-10865
    LY2183240
    2 Publications Verification

    		 FAAH Autophagy Neurological Disease
    LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. LY2183240 inactivates FAAH by carbamylation of the enzyme's serine nucleophile. LY2183240 also inhibits several other brain serine hydrolases with IC50s of 5.3, 0.09, 8.2 nM for MAG lipase, bh6 and KIAA1363, respectively .
    LY2183240
  • HY-W127407
    Glycerophospho-N-arachidonoyl ethanolamine

    		Biochemical Assay Reagents Others
    Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.
    Glycerophospho-N-arachidonoyl ethanolamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: